Top 5 Stocks to Buy Now
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:NCNA

NuCana Q1 2025 Earnings Report

NuCana logo
$1.91 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$1.90 -0.01 (-0.79%)
As of 06/18/2026 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

NuCana EPS Results

Actual EPS
-$126.00
Consensus EPS
-$2.58
Beat/Miss
Missed by -$123.42
One Year Ago EPS
N/A

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NuCana Announcement Details

Quarter
Q1 2025
Date
6/2/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

NuCana's next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

NuCana Earnings Headlines

NuCana plc Sponsored ADR
June 16, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/NCNA
NuCana Appoints Ian Webster as Chief Financial Officer
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304314/0/en/nucana-appoints-ian-webster-as-chief-financial-officer.html
SpaceX will crumble without these 5 companies
The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.tc pixel
June 21 at 1:00 AM  |  InvestPub (Ad)
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295318/0/en/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update.html
NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029
March 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/871927/nucana-posts-2025-results-highlights-nuc-7738-progress-and-cash-runway-into-2029/
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
March 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/19/3259416/0/en/nucana-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update.html
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients.

Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.

View NuCana Profile
Earnings Tools